Multidrug resistance (MDR-1) expression in AIDS-related lymphomas (Q43832871)

27 November 2017

title

Multidrug resistance (MDR-1) expression in AIDS-related lymphomas (English)

1 reference

27 November 2017

main subject

multiple drug resistance

1 reference

Anil Tulpule

1

1 reference

27 November 2017

Andy Sherrod

2

1 reference

27 November 2017

Dharshika Dharmapala

3

1 reference

27 November 2017

Lillian L Young

4

1 reference

27 November 2017

Byron M Espina

5

1 reference

27 November 2017

Maria Norilyn Sanchez

6

1 reference

27 November 2017

Parkash S Gill

7

1 reference

27 November 2017

Alexandra M Levine

8

1 reference

27 November 2017

publication date

1 February 2002

1 reference

27 November 2017

1 reference

27 November 2017

volume

26

1 reference

27 November 2017

issue

2

1 reference

27 November 2017

page(s)

121-127

1 reference

Molecular mechanisms of multidrug resistance in cancer chemotherapy

27 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2801%2900113-8

7 January 2021

Mechanisms of multidrug resistance and implications for therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2801%2900113-8

7 January 2021

The biochemistry of P-glycoprotein-mediated multidrug resistance

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2801%2900113-8

7 January 2021

Biochemistry of multidrug resistance mediated by the multidrug transporter

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2801%2900113-8

7 January 2021

The mdrl gene, responsible for multidrug-resistance, codes for P-glycoprotein

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2801%2900113-8

7 January 2021

https://api.crossref.org/works/10.1016%2FS0145-2126%2801%2900113-8

1 reference

7 January 2021

ATP-dependent transport of vinblastine in vesicles from human multidrug-resistant cells

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2801%2900113-8

7 January 2021

Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2801%2900113-8

7 January 2021

Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2801%2900113-8

7 January 2021

Expression of a multidrug-resistance gene in human tumors and tissues

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2801%2900113-8

7 January 2021

P-glycoprotein in Adult Hematologic Malignancies

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2801%2900113-8

7 January 2021

Multidrug resistance in lymphomas.

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2801%2900113-8

7 January 2021

P-glycoprotein expression in malignant lymphoma and reversal of clinical drug resistance with chemotherapy plus high-dose verapamil

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2801%2900113-8

7 January 2021

Immunohistochemical detection of multidrug resistance associated P-glycoprotein in tumour and stromal cells of human cancers

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2801%2900113-8

7 January 2021

Expression of P-glycoprotein and glutathione-S-transferase in recurrent lymphomas: the possible role of Epstein-Barr virus, immunophenotypes, and other predisposing factors

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2801%2900113-8

7 January 2021

Immunohistochemical detection of the multidrug transport protein P1 70 in human normal tissues and malignant lymphomas

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2801%2900113-8

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2801%2900113-8

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2801%2900113-8

7 January 2021

Lymphoid neoplasia associated with the acquired immunodeficiency syndrome (AIDS). The New York University Medical Center experience with 105 patients (1981-1986)

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2801%2900113-8

7 January 2021

Non-Hodgkin's lymphoma in a population with or at risk for acquired immunodeficiency syndrome: indications for intensive chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2801%2900113-8

7 January 2021

Low-dose chemotherapy with central nervous system prophylaxis and zidovudine maintenance in AIDS-related lymphoma. A prospective multi-institutional trial

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2801%2900113-8

7 January 2021

Low-dose compared with standard-dose m-BACOD chemotherapy for non-Hodgkin's lymphoma associated with human immunodeficiency virus infection. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2801%2900113-8

7 January 2021

Treatment of AIDS-Related Non-Hodgkin's Lymphoma with a Twelve Week Chemotherapy Program

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2801%2900113-8

7 January 2021

Human immunodeficiency virus-related lymphoma treatment with intensive combination chemotherapy. French-Italian Cooperative Group

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2801%2900113-8

7 January 2021

Low dose methotrexate, bleomycin, doxorubicin, cyclophosphamide, vincristine, and dexamethasone with zalcitabine in patients with acquired immunodeficiency syndrome-related lymphoma. Effect on human immunodeficiency virus and serum interleukin-6 lev

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2801%2900113-8

7 January 2021

Pilot trial of infusional cyclophosphamide, doxorubicin, and etoposide plus didanosine and filgrastim in patients with human immunodeficiency virus-associated non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2801%2900113-8

7 January 2021

Immunotoxin combined with chemotherapy for patients with AIDS-related non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2801%2900113-8

7 January 2021

National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphomas: summary and description of a working formulation for clinical usage. The Non-Hodgkin's Lymphoma Pathologic Classification Project

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2801%2900113-8

7 January 2021

A Network Algorithm for Performing Fisher's Exact Test in r × c Contingency Tables

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2801%2900113-8

7 January 2021

Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2801%2900113-8

7 January 2021

HIV-1 protease inhibitors are substrates for the MDR1 multidrug transporter.

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2801%2900113-8

7 January 2021

10.1016/S0145-2126(01)00113-8

Identifiers

DOI

1 reference

27 November 2017

1 reference